Jefferies raised the firm’s price target on Denali Therapeutics (DNLI) to $45 from $40 and keeps a Buy rating on the shares ahead of the company reporting first DNL-126 Phase 1/2 data in Sanfilippo Type A by year-end. Sanfilippo could “follow a very fast FDA path” and the drug has FDA START orphan designation for potentially fast regulatory path discussions, says the analyst, who thinks “strong and robust HS biomarker data” and good safety for Sanfilippo should help de-risk a second potential drug for Denali.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNLI:
- DNLI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Denali Therapeutics’ Oditrasertib Phase 2 Study Discontinued
- Denali Therapeutics reinstated with a Market Perform at Raymond James
- Denali Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Denali Therapeutics price target raised to $29 from $25 at BofA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
